Featured Studies

Researchers at the National Institutes of Health (NIH) are testing NX-2127, an oral drug that degrades a protein in cancer cells called Bruton's tyrosine kinase (BTK), instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate your immune T-cells to attack the cancer.

Doctors at the National Institutes of Health (NIH) seek healthy volunteers for a research study that is collecting bone marrow samples from healthy adults. Samples will be used for clinical research in the Hematology Branch and are indispensable for many research projects, including studies of normal and abnormal blood cells in the human body, blood diseases, the role of the immune system in marrow failure; and the genetic risk factors for aplastic anemia.

Heart disease is the leading cause of death and disability in the United States. Omega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers at the National Institutes of Health (NIH) want to find out more about these potential benefits.

Researchers at the National Institutes of Health (NIH) seek healthy volunteers to provide blood samples for research studies of blood vessels and immune diseases that cause clotting. In this study, investigators want to understand the basis of these diseases to facilitate the development of better treatments.

Research Study 000444-H investigating how well the following vaccines work in patients with CLL/SLL malignancies: SHINGRIX and influenza vaccine. If you are currently receiving treatment for your CLL/SLL (e.g. ibrutinib, acalabrutinib or venetoclax), you may be able to participate.

Healthy volunteers 18-60 years old are needed to test an investigational drug that was developed to reduce blood pressure in the lungs. The PAH team from @NHLBI hope that this investigational study drug may be helpful in treating patients with PAH in the future.

Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.